Gene Bio Systems
MTSS1 Antibody - Cat. #: CSB-PA098234
MTSS1 Antibody - Cat. #: CSB-PA098234
SKU:CSB-PA098234
Couldn't load pickup availability
Size :50ul
Clone Number:
Aliases:2310003N14Rik antibody; BC024131 antibody; D130001D01Rik antibody; DKFZp781P2223 antibody; FLJ44694 antibody; KIAA0429 antibody; metastasis suppressor 1 antibody; Metastasis suppressor protein 1 antibody; Metastasis suppressor YGL 1 antibody; Metastasis suppressor YGL-1 antibody; MGC37896 antibody; MIM antibody; MIMA antibody; MIMB antibody; missing in metastasis antibody; Missing in metastasis protein antibody; mKIAA0429 antibody; MTSS 1 antibody; Mtss1 antibody; MTSS1_HUMAN antibody
Product Type:Polyclonal Antibody
Immunogen Species:Homo sapiens (Human)
UniProt ID:O43312
Immunogen:Synthetic peptide of Human MTSS1
Raised in:Rabbit
Species Reactivity:Human, Mouse
Tested Applications:ELISA, IHC; ELISA:1:1000-1:2000, IHC:1:25-1:100
Background:MTSS1 (metastasis suppressor 1), also known as MIM, MIMA or MIMB, is a 755 amino acid protein that contains one Actin-binding WH2 (Wiskott-Aldrich syndrome protein homology-2) domain and one IMD domain. Expressed in a variety of tissues including testis, thymus, prostate, spleen, colon, uterus and blood, MTSS1 is thought to bind to Actin and, via this binding, may affect the dynamics of the cytoskeleton. Through its association with the cytoskeleton, MTSS1 plays a role in controlling the progression and metastasis of carcinomas in various organ sites throughout the body and, when expressed at normal levels, functions as a tumor suppressor. Overexpression of MTSS1 results in the formation of abnormal actin structures, an event that may lead to tumorigenesis. Three isoforms of MTSS1 exist due to alternative splicing events.
Clonality:Polyclonal
Isotype:IgG
Purification Method:Antigen affinity purification
Conjugate:Non-conjugated
Buffer:-20°C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol
Form:Liquid
Stroage:Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Target Names:MTSS1
Research Areas:Epigenetics and Nuclear Signaling;Cancer;Signal transduction
